Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female healthy volunteer subjects, between 25 and 70 years of age, giving informed consent for facial laser ablation of the lower eyelid areas for the purpose of wrinkle removal.~* Lower eyelid skin is free of any irritation, scarring or dermatologic conditions which might interfere with the study.~* Willing and able to participate in the study and follow all study directions.~* Able to read, understand and sign the consent form prior to any study related procedures.~Exclusion Criteria:~* Female subjects who are pregnant, nursing, or planning a pregnancy during the course of the study, as determined by the interview and a urine pregnancy test.~* Presence of irritation or dermatologic skin conditions in the lower eyelid area.~* Known allergies to materials within the test formulations (i.e., yeast and/or yeast products).~* Use of topical or systemic drugs (corticosteroids, retinoids, immune modulators, immune suppressants, drugs with potential for contact dermatitis, drugs with potential for skin discoloration) that may have an effect on wound healing or may impact skin pigmentation.~* A history, upon wounding, of developing thickened scars, keloids, or excessive pigment change.~* An unstable or severe inter-current medical condition that, in the opinion of the investigator, might interfere with interpretation of study results or render the subject at high risk for treatment complications.~* Use of any investigational medication or device for any indication within 30 days of screening.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): GLYC-101 Gel, 0.1% on one eyelid and Placebo Gel on the other eyelid
- 2 (Type: EXPERIMENTAL): GLYC-101 Gel, 1.0% on one eyelid and Placebo Gel on the other eyelid
- 3 (Type: EXPERIMENTAL): GLYC-101 Gel, 0.1% on one eyelid and GLYC-101 Gel, 1.0% on the other eyelid

Based on this trial design, predict the completion outcome and termination type (if applicable).